In particular, PRL-3 is a well-defined biomarker of metastasis in multiple cancer types, including melanoma, colorectal, and ovarian cancer, where PRL-3 expression is significantly higher in metastatic lesions compared to the primary tumor site7–15. This evidence concerns the gene PTP4A3 and ovarian carcinoma.